JMJD6 Enzyme Drives Cancer Growth and Shields Tumors from Immune Attack

Cancer remains one of the most complex challenges in medicine, partly because tumors exploit both internal growth programs and external immune-suppressive mechanisms to survive. Understanding enzymes that simultaneously drive both processes could open powerful new therapeutic avenues.

This 2026 review from West China Hospital examines JMJD6, an iron- and α-ketoglutarate-dependent dioxygenase with multiple enzymatic activities spanning epigenetic and post-transcriptional regulation. The enzyme is frequently overexpressed across diverse cancer types and consistently correlates with poor patient prognosis, positioning it as a clinically significant molecular player.

On the oncogenic side, JMJD6 promotes tumor cell proliferation, invasion, metastasis, and stemness by hydroxylating p53 — effectively dampening this key tumor suppressor — and by activating the β-catenin/c-Myc signaling pathway, a well-known driver of aggressive cancer behavior. On the immunological side, JMJD6 reshapes the tumor microenvironment by driving macrophage polarization toward the immunosuppressive M2 phenotype through the STAT3/IL-10 signaling axis, helping tumors evade immune destruction.

The review argues that JMJD6 acts as a molecular bridge connecting intrinsic cancer cell programs with the extrinsic suppression of anti-tumor immunity. This dual functionality makes it an especially attractive target, and the authors survey emerging small-molecule JMJD6 inhibitors as well as combination strategies pairing such inhibitors with immune checkpoint inhibitors like PD-1/PD-L1 blockade.

Important caveats remain: most mechanistic insights derive from preclinical models, no JMJD6-targeted therapy has yet reached clinical approval, and the full spectrum of JMJD6's tissue-specific roles is not yet understood. Nonetheless, the convergence of oncogenic and immune-evasive functions in a single druggable enzyme makes JMJD6 a high-priority subject for translational oncology research.